--- title: "Medifast’s Earnings Call: Balancing Challenges and Progress" type: "News" locale: "en" url: "https://longbridge.com/en/news/264320585.md" description: "Medifast's recent earnings call highlighted both achievements and challenges. The company reported a significant revenue decline of 36.2% to $89.4 million and a net loss of $2.3 million. Despite a 35% decrease in active OPTAVIA coaches, Medifast remains optimistic about future growth through new product launches and strategic programs. The company maintains a strong financial position with $173.5 million in cash and no debt. Promising clinical research findings support their health approach, and a new product line is set to launch in 2026, focusing on metabolic health." datetime: "2025-11-05T01:10:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/264320585.md) - [en](https://longbridge.com/en/news/264320585.md) - [zh-HK](https://longbridge.com/zh-HK/news/264320585.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264320585.md) | [繁體中文](https://longbridge.com/zh-HK/news/264320585.md) # Medifast’s Earnings Call: Balancing Challenges and Progress Medifast’s recent earnings call presented a balanced perspective, highlighting both the company’s achievements and challenges. While Medifast showcased significant progress in clinical research and maintained a robust financial position, it also faced notable revenue declines and a reduction in active coaches. Despite these challenges, the company remains optimistic about future growth through new product launches and strategic programs. ## Clinical Research Findings Medifast announced promising clinical research findings, demonstrating that their program retains 98% of lean mass, reduces visceral fat by 14%, and improves body composition during weight loss. These results underscore the effectiveness of Medifast’s approach to health and wellness, providing a strong foundation for future product development. ## Strong Financial Position The company maintains a solid financial footing with $173.5 million in cash, cash equivalents, and investments, and no interest-bearing debt. This strong balance sheet positions Medifast well to navigate current challenges and invest in future growth initiatives. ## New Product Line Announcement Medifast is set to launch a new product line next year, utilizing metabolic synchronization science and next-generation ingredients aimed at enhancing metabolic health. This strategic move is expected to differentiate Medifast in the competitive health and wellness market. ## Initial Positive Response to Premier+ Program The Premier+ pricing and auto ship program has received a positive initial response, with an increase in baseline client retention beyond the first month. This program could play a crucial role in stabilizing client engagement and driving future revenue. ## Significant Revenue Decline The third quarter saw a significant revenue decline, with figures dropping to $89.4 million, a 36.2% decrease from the previous year. This downturn is attributed to a reduction in active earning OPTAVIA coaches. ## Decrease in Active Coaches There was a notable 35% decrease in the number of active earning OPTAVIA coaches compared to the third quarter of 2024. This decline poses a challenge for Medifast as it impacts revenue generation and client engagement. ## Net Loss Reported Medifast reported a net loss of $2.3 million in the third quarter of 2025, translating to a $0.21 loss per diluted share. This contrasts with a net income of $1.1 million or $0.10 per share in the same period last year, highlighting the financial pressures faced by the company. ## Uncertain Future Revenue Looking ahead, Medifast projects fourth-quarter revenue to range between $65 million and $80 million, indicating ongoing revenue challenges. The company is preparing for a strategic pivot towards metabolic health, which may help stabilize and grow revenue in the long term. ## Forward-Looking Guidance Medifast provided forward-looking guidance that reflects a strategic shift towards addressing metabolic health rather than solely focusing on weight loss. The company expects fourth-quarter revenue to range from $65 million to $80 million, with a projected loss per share between $0.70 and $1.25. Medifast is also gearing up to launch a new product line in 2026, leveraging their metabolic synchronization science to stand out in the market. In summary, Medifast’s earnings call painted a picture of both challenges and opportunities. While facing revenue declines and a decrease in active coaches, the company remains optimistic about its strategic initiatives and new product launches. Medifast’s strong financial position and promising clinical research findings provide a solid foundation for future growth, as the company pivots towards a focus on metabolic health. ### Related Stocks - [Medifast, Inc. (MED.US)](https://longbridge.com/en/quote/MED.US.md) ## Related News & Research - [Raymond James Financial Earnings Preview: What to Expect](https://longbridge.com/en/news/281024632.md) - [Here's What to Expect From CBRE Group's Next Earnings Report](https://longbridge.com/en/news/281323999.md) - [Mochi Health and Livelong Women's Health Summit Partner to Advance Women's Metabolic Health](https://longbridge.com/en/news/280827047.md) - [Norfolk Southern Earnings Preview: What to Expect](https://longbridge.com/en/news/280999046.md) - [Lexaria Bolsters Global Patent Portfolio With New GLP-1 and Cardiometabolic IP](https://longbridge.com/en/news/280651700.md)